Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 72

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 72
---
 STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

NOTE
3 — INITIAL PUBLIC OFFERING

Pursuant
to the Initial Public Offering consummated on January 29, 2025, the Company sold 20,000,000 Units at a price of $10.00 per Unit. Each
Unit consists of one ordinary share and one right (“Public Right”), with each Public Right entitling the holder to receive
one-eighth (1/8) of one ordinary share upon the consummation of an initial business combination. In connection with the Initial Public
Offering, the underwriters were granted a 45-day option to purchase up to 3,000,000 additional Units to cover over-allotments, if any.
On February 18, 2025, the underwriters exercised their option to purchase an additional 3,000,000 Units at a purchase price of $10.00
per Unit, generating additional gross proceeds of $30,000,000.

NOTE
4 — PRIVATE PLACEMENT

Simultaneously
with the closing of the Initial Public Offering, the Company consummated the sale of 400,000 Private Placement Units at a price of
$10.00 per Private Placement Unit in a private placement to the Sponsor, for $4,000,000, of which $1,100,000 was not received and
included as share subscription receivable. Since the Initial Public Offering until September 30, 2025, the Sponsor has paid $491,178
in expenses on behalf of the Company (including $81,000 related to the administrative support agreement) affecting the share
subscription receivable on the unaudited balance sheet to $608,822. Each Private Placement Unit consists of one ordinary share and
one right to receive one-eighth (1/8) of one ordinary share upon the consummation of an initial business combination. The proceeds
from the sale of the Private Placement Units are added to the net proceeds from the Initial Public Offering held in the Trust
Account. Simultaneously with the sale of the over-allotment option Units on February 18, 2025, the Sponsor purchased an additional
30,000 Private Placement Units at a purchase price of $10.00 per Private Placement Unit, generating additional gross proceeds of
$300,000. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of